Abstract
ObjectiveAn increasing body of evidence suggests that immunological changes may play a role in schizophrenia but the results of the studies are controversial and little is known about the presence of those changes at the onset of the disease. Our aim is to compare the levels of interleukin (IL) IL-2, IL-6, IL-10, IL-17 and transforming growth factor -β2 (TGF-β2) between drug-naïve-first episode patients with psychosis and healthy controls matched for age, sex, BMI and smoking. MethodsThirty-nine drug-naïve-first episode patients with psychosis and 39 healthy individuals (control group) were enrolled in the study. Serum levels of IL-2, IL-6, IL-10, IL-17 and TGF-β2 were measured by enzyme linked immunosorbent assay (ELISA). ResultsSerum IL-2 and IL-6 levels were significantly higher in the drug-naïve patients with psychosis group (p<0.022 and p<0.002 respectively) compared to healthy controls. No differences were found between the two groups in the levels of IL-10, IL-17. The levels of TGF-β2 did not differ significantly between the two groups. ConclusionThe serum levels of IL-2 and IL-6 are increased in first episode drug-naïve patients with psychosis compared to healthy controls. An inflammatory response mediated by IL-2 and IL-6 may play a role in schizophrenia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
